Two‐year follow‐up comparing Rezūm therapy versus bipolar transurethral resection of the prostate for treating benign prostatic hyperplasia. A prospective randomized study

Abstract

ObjectiveComparison of the efficacy and safety of Rezūm therapy and bipolar transurethral resection of prostate (B‐TURP) for the management of benign prostatic hyperplasia (BPH) of 50–120 g size.MethodsOne hundred patients with BPH who met the inclusion criteria were included and split into two equal groups to undergo Rezūm therapy or B‐TURP. The two groups were compared for efficacy using international prostate symptom score (IPSS), quality of life (QoL), maximum urinary flow rate (Qmax), operative time, catheter time, hospital stay, post‐void residual urine (PVR), prostate‐specific antigen (PSA), and residual prostate size and safety using the incidence of complications.ResultsRezūm significantly ameliorated IPSS from the baseline score by 55.3%, QoL by 50%, Qmax by 62.5%, International Index of Erectile Function (IIEF) by 7.1%, PVR by 50%, residual prostate size by 28.1% and PSA by 42% at 2 years. Meanwhile, the improvement in B‐TURP was significantly higher than Rezūm group, Rezūm therapy had a significantly shorter duration of operative time and hospital stay. Also, it had fewer complications in comparison with B‐TURP.ConclusionsRezūm is a minimally invasive procedure that provides significantly improved symptomatic relief of BPH and quality of life with preservation of erectile and ejaculatory functions. However, it is not as effective as B‐TURP.